VivaGel« BV treatment clinical submission under rolling NDA

21 December 2017

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has completed the VivaGel® BV treatment clinical section of the NDA clinical module, which will be submitted to the FDA under Starpharma’s rolling submission on Friday 22 December 2017 (US time). 

Read more

© Starpharma Holdings Limited 2017